Glutamate agonists for schizophrenia stimulate dopamine D2High receptors

Schizophrenia Research

Volumn 99, Issue 1-3, 2008, Pages 373-374

  Seeman, Philip ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; ARIPIPRAZOLE; DOMPERIDONE; DOPAMINE 2 RECEPTOR; EGLUMETAD; GLUTAMATE RECEPTOR AGONIST; LY 404039; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; NEUROLEPTIC AGENT; PROLACTIN; SPIPERONE; UNCLASSIFIED DRUG;

ADENOHYPOPHYSIS; BINDING AFFINITY; CELL ISOLATION; DISSOCIATION CONSTANT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; HUMAN; LETTER; PRIORITY JOURNAL; SCHIZOPHRENIA;

AMINO ACIDS; ANTIPSYCHOTIC AGENTS; BICYCLO COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; BRAIN; CYCLIC S-OXIDES; DOPAMINE AGONISTS; EXCITATORY AMINO ACID AGONISTS; HUMANS; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 39149141396     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.11.007     Document Type: Letter

References (10)

1. Cosi C., Carilla-Durand E., Assie M.B., et al. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur. J. Pharmacol. 535 1-3 (2006) 135-144
2. Johnson B.G., Wright R.A., Arnold M.B., et al. [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology 38 10 (1999) 1519-1529
3. Monn J.A., Valli M.J., Massey S.M., et al. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J. Med. Chem. 42 6 (1999) 1027-1040
4. Patil S.T., Zhang L., Martenyi F., et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 13 9 (2007) 1100-1105
5. Schoepp D.D., Jane D.E., and Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38 10 (1999) 1431-1476
6. Seeman P., Chau-Wong M., Tedesco J., and Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc. Natl. Acad. Sci. U.S.A. 72 11 (1975) 4376-4380
7. 3H]spiperone in isotonic medium: Implications for human positron emission tomography. Synapse 49 4 (2003) 209-215
8. Seeman, P., Caruso, C., Lasaga, M. 2008. Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268. Synapse 62 (2), 154-158.
9. Van Rossum J.M. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H., Cole J.O., Deniker P., Hippius H., and Bradley P.B. (Eds). Neuro-Psycho-Pharmacology, Proceedings of the Fifth International Congress of the Collegium Internationale Neuro-Psycho-pharmacologicum, March 1966 (1967), Excerpta Medica Foundation, Amsterdam 321-329
10. Weinberger D.R. Schizophrenia drug says goodbye to dopamine. Nat. Med. 13 9 (2007) 1018-1019